Simplified Chinese
Indigenously developed vaccines are making their way overseas, as China contributes to safeguarding global health and well-being!
Release date:
2019-04-24
Author:
Contributed by the General Office
Source:
Abstract
A 2016 study showed that for every dollar invested in childhood vaccination, the return on investment amounts to $44—far exceeding the $3 return on investment in infrastructure. Today, China has become the world’s largest vaccine producer and has reaped substantial benefits from immunization; however, according to a WHO report, one in ten newborns worldwide still remains unvaccinated. Consequently, as domestically produced vaccines expand into international markets, they not only contribute to global health security but also further reinforce China’s image as a responsible major country.
On December 27 last year, Pakistan’s Forum Express published a news item that sent shockwaves through the industry: Pakistan’s National Institute of Health had resumed production of measles vaccine after a seven-year hiatus. The concentrated measles vaccine used in this batch was sourced entirely from Beijing Minhai Biotechnology Co., Ltd. in China, marking the first time China has exported measles‑vaccine concentrate to Pakistan.
Being able to supply measles vaccine concentrate that meets Pakistan’s national standards is a significant achievement for a private enterprise that has existed for just over a decade. The team at Minhai has remained down-to-earth, advancing steadily step by step, and through their dedicated efforts, they are turning the “Chinese Dream” of the vaccine industry into reality.
In Minhai Biologics’ R&D laboratory, multiple vaccine projects are advancing in parallel. Since its establishment in 2004, in just over a decade, the company has progressed from importing vaccines from abroad to achieving fully independent research and development, integrating into the national immunization program, and exporting four self-developed and manufactured vaccines to four countries—successes that are far from easily replicable.
Vaccine development requires a lengthy time frame; it is by no means possible to see results just two days after investment. Consequently, for vaccine research, eight years is not considered long, and twenty years is quite common—this is a “path to safeguarding lives” that offers no shortcuts to disease immunity.
To align with the World Health Organization’s Global Polio Eradication Initiative, Minhai Biotechnology has exclusively imported from abroad the production technology for the Sabin‑strain inactivated poliovirus vaccine; accordingly, the newly acquired production line equipment has now been largely installed and commissioned.
Eric Giraud, Senior Mechanical Engineer at the French company PIERRE GUERIN SAS:
This French company has already earned recognition from numerous Chinese enterprises, and it is widely regarded as the global leader in the biopharmaceutical industry.
Zhang Xianchen, Project Leader of the sIPV Program at Beijing Minhai Biotechnology Co., Ltd.:
Since 2014, we have conducted extensive process research and optimization. Previously, a single production line could yield approximately 100,000 doses per batch; today, we can produce 400,000 doses, representing nearly a fourfold increase.
The export of measles vaccines to Pakistan does not mean that domestically produced vaccines will enjoy a smooth path into the international market. Aligning with global standards and meeting relevant international requirements is a challenge that every domestic vaccine manufacturer must address. Moreover, breaking through technological blockades and trade barriers—and ensuring that our vaccines can be safely transported over long distances under strict cold-chain conditions—represents a series of critical hurdles that our companies must overcome one by one.
Aligning with international standards is no simple task. Behind every negotiation—where smiles and easy conversation prevail at the table—lies a tremendous investment of time and effort in data collection, investigation, research, and deliberation. Each agreement signed carries the sincerity and heartfelt commitment of all those involved; every word put on paper is worth its weight in gold.
At present, China has become the world’s largest vaccine producer, capable of manufacturing more than 60 types of vaccines to prevent 34 diseases. This includes pioneering global innovations such as the Ebola vaccine and the H1N1 influenza vaccine. As an increasing number of domestically produced vaccines obtain approval and certification from the World Health Organization, Chinese-made vaccines entering the international market will contribute to global health security and greater equity in vaccine access.
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09
Contact Information
Customer Service Hotline
4001899806
Phone number
010-59613600
Official Website
Company Address
No. 35 Simiao Road and No. 25 Tianfu Street, Daxing Biomedical Industry Base, Zhongguancun Science Park, Daxing District, Beijing
WeChat Official Account